Kamrouz Ghadimi

Kamrouz Ghadimi

Auto-generated profile, based on publicly available information

Kamrouz Ghadimi

Department of Anesthesiology, Duke University, Durham, North Carolina

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in Anesthesiology
Verified
Journal Article
Open access
PDF file
GEGabor Erdoes
Gabor Erdoes
DFDavid Faraoni
David Faraoni
AKAndreas Koster
Andreas Koster
MSMarie Steiner
Marie Steiner
KGKamrouz Ghadimi
Kamrouz Ghadimi
Jerrold H LevyJerrold H Levy
Jerrold H Levy
Inherited and acquired coagulopathy are frequently associated with major bleeding in severe trauma, cardiac surgery with cardiopulmonary bypass, and postpartum hemorrhage. Perioperative management is multifactorial and includes preoperative optimization and discontinuation of anticoagulants and antiplatelet therapy in elective procedures. Prophylactic or therapeutic use of antifibrinolytic agents is strongly recommended in guidelines and has been shown to reduce bleeding and need for allogeneic blood administration. In the context of bleeding induced by anticoagulants and/or antiplatelet therapy, reversal strategies should be considered when available. Targeted goal-directed therapy using viscoelastic point-of-care monitoring is increasingly used to guide the administration of coagulation factors and allogenic blood products. In addition, damage control surgery, which includes tamponade of large wound areas, leaving surgical fields open, and other temporary maneuvers, should be considered when bleeding is refractory to hemostatic measures.

14 April 2023 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
Jerrold H LevyJerrold H Levy
Jerrold H Levy
KGKamrouz Ghadimi
Kamrouz Ghadimi
JKJayachandran N. Kizhakkedathu
Jayachandran N. Kizhakkedathu
Toshiaki IbaToshiaki Iba
Toshiaki Iba

24 October 2023 in Circulation
Verified
Journal Article
Closed access
KGKamrouz Ghadimi
Kamrouz Ghadimi
JCJhaymie L. Cappiello
Jhaymie L. Cappiello
MWMary Cooter Wright
Mary Cooter Wright
Jerrold H LevyJerrold H Levy
Jerrold H Levy
BBBenjamin S. Bryner
Benjamin S. Bryner
FIfor the INSPIRE-FLO Investigators
for the INSPIRE-FLO Investigators
BACKGROUND: Right ventricular failure (RVF) is a leading driver of morbidity and death after major cardiac surgery for advanced heart failure, including orthotopic heart transplantation and left ventricular assist device implantation. Inhaled pulmonary-selective vasodilators, such as inhaled epoprostenol (iEPO) and nitric oxide (iNO), are essential therapeutics for the prevention and medical management of postoperative RVF. However, there is limited evidence from clinical trials to guide agent selection despite the significant cost considerations of iNO therapy. METHODS: In this double-blind trial, participants were stratified by assigned surgery and key preoperative prognostic features, then randomized to continuously receive either iEPO or iNO beginning at the time of separation from cardiopulmonary bypass with the continuation of treatment into the intensive care unit stay. The primary outcome was the composite RVF rate after both operations, defined after transplantation by the initiation of mechanical circulatory support for isolated RVF, and defined after left ventricular assist device implantation by moderate or severe right heart failure according to criteria from the Interagency Registry for Mechanically Assisted Circulatory Support. An equivalence margin of 15 percentage points was prespecified for between-group RVF risk difference. Secondary postoperative outcomes were assessed for treatment differences and included: mechanical ventilation duration; hospital and intensive care unit length of stay during the index hospitalization; acute kidney injury development including renal replacement therapy initiation; and death at 30 days, 90 days, and 1 year after surgery. RESULTS: Of 231 randomized participants who met eligibility at the time of surgery, 120 received iEPO, and 111 received iNO. Primary outcome occurred in 30 participants (25.0%) in the iEPO group and 25 participants (22.5%) in the iNO group, for a risk difference of 2.5 percentage points (two one-sided test 90% CI, –6.6% to 11.6%) in support of equivalence. There were no significant between-group differences for any of the measured postoperative secondary outcomes. CONCLUSIONS: Among patients undergoing major cardiac surgery for advanced heart failure, inhaled pulmonary-selective vasodilator treatment using iEPO was associated with similar risks for RVF development and development of other postoperative secondary outcomes compared with treatment using iNO. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03081052.

1 May 2019 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
BBBrandi A. Bottiger
Brandi A. Bottiger
ANAlina Nicoara
Alina Nicoara
LSLaurie D. Snyder
Laurie D. Snyder
PWPaul E. Wischmeyer
Paul E. Wischmeyer
JSJacob N. Schroder
Jacob N. Schroder
KGKamrouz Ghadimi
Kamrouz Ghadimi

22 August 2023 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
Jerrold H LevyJerrold H Levy
Jerrold H Levy
RSRoman M. Sniecinski
Roman M. Sniecinski
BRBianca Rocca
Bianca Rocca
KGKamrouz Ghadimi
Kamrouz Ghadimi
JDJames Douketis
James Douketis
JCJean Connors
Jean Connors

1 May 2021 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
MMMichael W. Manning
Michael W. Manning
YLYi-Ju Li
Yi-Ju Li
DLDean Linder
Dean Linder
JHJohn C. Haney
John C. Haney
YWYi-Hung Wu
Yi-Hung Wu
KGKamrouz Ghadimi
Kamrouz Ghadimi